Fulcrum Therapeutics made a decisive strategic pivot in late 2024, discontinuing its losmapimod program for facioscapulohumeral muscular dystrophy (FSHD). This decision followed disappointing Phase 3 REACH trial results, which did not demonstrate a statistically significant difference from placebo.
The discontinuation of the losmapimod program also led to the termination of Fulcrum's collaboration with Sanofi. Concurrently, the company implemented a workforce reduction of approximately 40% to reprioritize resources.
This bold move was designed to sharpen the company's focus and capital allocation on its most promising assets, primarily pociredir for sickle cell disease and its preclinical pipeline in inherited aplastic anemias.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.